Astellas to Acquire US Gene Therapy Venture Audentes Dec. 6, 2019 Filed Under: Pharma Tagged With: Astellas Pharma, Audentes, gene therapy, M&A, rare diseasesAstellas Pharma Inc. (TYO:4503) recently announced that it has agreed to acquire Audentes Therapeutics Inc., a U.S.-based venture specializing in…... Please subscribe to read the full story. Subscribe Free Trial Related Articles:AGC in Race to Bolster CDMO Operations Across US, Europe and…AGC Plans to Invest Over 200B Yen in CDMO Operations for…India Moves to Shed Dependence on China for Active…Evonik Plans Further Investment in mRNA Field to Expand…DIC Builds Biotech Platform to Aid in Creating New BusinessBig Pharma in Big Push to Increase Use of Biomass Materials…